Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs

Psilocybin microdosing does not reduce symptoms of depression or anxiety, according to placebo-controlled study

by Eric W. Dolan
February 7, 2022
in Mental Health, Microdosing, Psilocybin, Psychedelic Drugs
Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

Consuming small doses of psilocybin at regular intervals — a process known as microdosing — does not appear to improve symptoms of depression or anxiety, according to new research published in the Journal of Psychopharmacology. The placebo-controlled study casts doubt on claims that microdosing psychedelic drugs can improve mental health.

Regular doses of psilocybin — the active component in so-called “magic” mushrooms — have been shown to have profound and long-lasting effects on personality and mood. Preliminary research has indicated that microdosing psychedelic drugs is also associated with a range of psychological benefits, such as increased productivity and reduced stress. In one study, nearly 80% of individuals who microdosed with psychedelics reported improvements in their mental health.

But much of the research on microdosing has come with important limitations: namely, the lack of placebo control groups.

“The main interest in this topic stems from anecdotal reports of people who microdose and say they experience the beneficial effects. Many people do this in order to feel better, to have a more optimistic outlook on life and to cope with depression and anxiety,” said study author Michiel van Elk, an associate professor of cognitive psychology at Leiden University and supervisor of the PRiSM Lab.

“However, most research on this topic was cross-sectional in nature. This means that the research asked a group of people at a specific point in time whether they microdosed and how they were feeling. This type of research showed that microdosing was associated with better mental health.”

“But correlation does not imply causation,” van Elk explained. “It could be that the participants in those studies self-selected because they experienced the beneficial effects of microdosing. It could also be that placebo effects were at play, as people knew they were actually taking a microdose. Thus, in order to obtain more causal evidence for the effects of microdosing on emotional processing and well-being, we needed to conduct a placebo-controlled study.”

The study included a carefully screened sample of 75 participants who attended a microdosing workshop. At the end of the workshop, the participants received two bags that contained either psilocybin pills or placebo pills. The researchers instructed the participants to consume one bag of doses over the following three weeks. The participants then took a two-week break, before consuming the second bag of doses for the next three weeks.

Neither the participants nor the researchers were aware of which bag contained psilocybin and which bag contained placebo, a process known as double-blinding. Participants were also excluded from the final analysis if they consumed other psychoactive substances during the study or deviated from their microdosing schedule.

In four laboratory sessions, which took place about 1.5 hours after self-administering a dose of psilocybin or placebo, the participants completed a battery of tests that measured depression, anxiety, emotion processing, and interoceptive awareness.

Based on previous findings, the researchers had expected that psilocybin microdosing would reduce symptoms of anxiety and depression, induce a bias towards positive facial expressions, and increase interoceptive awareness. But the effects of microdosing did not differ significantly from placebo.

“We found that microdosing with psilocybin compared to a placebo did not result in reduced depression or anxiety scores,” van Elk told PsyPost. “We observed a strong generic placebo-effect though: both the placebo and the microdosing group showed a significant change in their wellbeing scores from the moment they started with the study. Thus, merely expecting that you are part of a clinical trial during which you might or might not receive a psychoactive substance already improves your wellbeing.”

The findings are in line with another placebo-controlled study, which found that small doses of LSD did not have significant effects on a test of working memory, a test of cognitive functioning, or a measure of simulated social exclusion. But it is still possible that microdosing has some positive psychological impacts. The scientific investigation into microdosing — and the use of psychedelic substances in general — is still in its infancy.

“Of course, this does not mean that microdosing is completely ineffective,” van Elk said. “We only found no objective evidence in our controlled study. But there are indeed many caveats. It could well be that the dosing we used was suboptimal and needs to be fine-tuned on an individual basis. It could also be that it takes some time for microdosing to take effect and that merely doing this for a few weeks is not enough to establish the long-term effects.”

“Another caveat is that many people in our study broke blind and they figured out what condition they were assigned to,” van Elk added. “This is a more generic problem for this type of research: the effects of psychedelics are so obvious — even at lower doses — that it is difficult to prevent people from figuring out what condition they are assigned to. If people subsequently figure out that they are in the active/experimental condition (e.g., based on subtle side-effects), this in turn can contribute again to the placebo response.”

Future studies should utilize larger sample sizes, which would make it easier to detect small effects, the researchers said.

“So in short: we found that psilocybin microdosing does not affect emotional processing and wellbeing,” van Elk said. “It could well be however that are study design was simply not sufficiently sensitive to pick up any signal that might be present in people who microdose. We need research that is more ecologically valid and that can study people in their daily lives and natural environments, rather than in a lab-based context. Smart wearables and experience-sampling techniques are important tools that can be used to this end.”

The study, “Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study“, was authored by Josephine Marschall, George Fejer, Pascal Lempe, Luisa Prochazkova, Martin Kuchar, Katerina Hajkova, and Michiel van Elk.

RELATED

ADHD

Altered brain activity patterns affect ADHD risk, not vice versa

October 20, 2025
New study links mother’s selfie habits to her teen’s interest in cosmetic surgery
Body Image and Body Dysmorphia

New study links mother’s selfie habits to her teen’s interest in cosmetic surgery

October 19, 2025
Scientists find a difficult past may create a kind of psychological inoculation against future stress
Depression

Scientists find a difficult past may create a kind of psychological inoculation against future stress

October 19, 2025
Sexual consent tends to decline with age for women who have experienced nonconsensual sex
Mental Health

Sexual consent tends to decline with age for women who have experienced nonconsensual sex

October 19, 2025
Teens who use cannabis are 11 times more likely to develop a psychotic disorder
Cannabis

Cannabis use in adolescents is associated with more frequent psychotic-like experiences

October 19, 2025
Psychiatrists detail bizarre case of incubus syndrome triggered by alcohol withdrawal
Mental Health

Psychiatrists detail bizarre case of incubus syndrome triggered by alcohol withdrawal

October 18, 2025
Women who have larger breasts tend to have lower levels of satisfaction with their breasts, study finds
Body Image and Body Dysmorphia

Women with larger breasts tend to report higher self-esteem, study finds

October 18, 2025
Scientists uncover previously unknown target of alcohol in the brain: the TMEM132B-GABAA receptor complex
Anxiety

New study reveals how the brain learns to adapt to harmless threats

October 17, 2025

STAY CONNECTED

LATEST

Altered brain activity patterns affect ADHD risk, not vice versa

The psychology of scary fun: New study reveals nearly all children enjoy “recreational fear”

New study finds creativity supports learning through novel mental connections

Review of 12 years of research highlights gaps in knowledge about non-binary sexual health

Early-life sugar restriction is linked to lower adult asthma and COPD risk, study finds

People who love horror movies tend to exhibit certain personality traits, study finds

New study links mother’s selfie habits to her teen’s interest in cosmetic surgery

Scientists find a difficult past may create a kind of psychological inoculation against future stress

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy